FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2119285905> ?p ?o ?g. }

• W2119285905 endingPage "n/a" @default.
• W2119285905 startingPage "n/a" @default.
• W2119285905 abstract "Objective Olanzapine augmentation of fluoxetine, a selective serotonin reuptake inhibitor, is an effective augmentation therapy for treatment-resistant depression (TRD). However, studies of olanzapine augmentation of other antidepressants are few. We investigated the efficacy and safety of olanzapine augmentation of milnacipran, a serotonin–norepinephrine reuptake inhibitor, for TRD. Methods This study covered patients with stage 2 TRD, defined by Thase and Rush. Olanzapine was added to milnacipran, and its dosage was adjusted according to each patient. Previous treatments were continued, but no new treatments were allowed. Response was measured using Hamilton Depression Rating Scale (HAMD) and Clinical Global Impression at weeks 0, 1, 2, 3, 4, and 8. Results Eleven patients aged 53.2 ± 24.0 years received olanzapine at 5.0 ± 1.9 mg/day with milnacipran. HAMD and Clinical Global Impression scores improved significantly from baseline to endpoint. This improvement occurred in week 1. At endpoint, seven of 11 (64%) were responders on HAMD (≥50% reduction). Four patients (36%) discontinued the trial because of no efficacy. No severe adverse effect occurred. Conclusions Olanzapine augmentation of milnacipran for stage 2 TRD might be effective and well tolerated. However, our study is open label and uncontrolled. Therefore, a double-blind controlled trial is necessary to confirm our results. Copyright © 2011 John Wiley & Sons, Ltd." @default.
• W2119285905 created "2016-06-24" @default.
• W2119285905 creator A5013673807 @default.
• W2119285905 creator A5032763504 @default.
• W2119285905 creator A5054302897 @default.
• W2119285905 creator A5059429675 @default.
• W2119285905 creator A5069223833 @default.
• W2119285905 creator A5069321417 @default.
• W2119285905 date "2011-06-01" @default.
• W2119285905 modified "2023-09-27" @default.
• W2119285905 title "Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open study" @default.
• W2119285905 cites W1539952678 @default.
• W2119285905 cites W1978223495 @default.
• W2119285905 cites W1981005549 @default.
• W2119285905 cites W2002943100 @default.
• W2119285905 cites W2011642949 @default.
• W2119285905 cites W2046403378 @default.
• W2119285905 cites W2054507400 @default.
• W2119285905 cites W2068485725 @default.
• W2119285905 cites W2078374346 @default.
• W2119285905 cites W2080784754 @default.
• W2119285905 cites W2113922703 @default.
• W2119285905 cites W2114693958 @default.
• W2119285905 cites W2126739761 @default.
• W2119285905 cites W2157877920 @default.
• W2119285905 cites W2313825065 @default.
• W2119285905 cites W3164656276 @default.
• W2119285905 cites W4231169313 @default.
• W2119285905 doi "https://doi.org/10.1002/hup.1197" @default.
• W2119285905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21638328" @default.
• W2119285905 hasPublicationYear "2011" @default.
• W2119285905 type Work @default.
• W2119285905 sameAs 2119285905 @default.
• W2119285905 citedByCount "5" @default.
• W2119285905 countsByYear W21192859052012 @default.
• W2119285905 countsByYear W21192859052013 @default.
• W2119285905 countsByYear W21192859052014 @default.
• W2119285905 countsByYear W21192859052015 @default.
• W2119285905 countsByYear W21192859052021 @default.
• W2119285905 crossrefType "journal-article" @default.
• W2119285905 hasAuthorship W2119285905A5013673807 @default.
• W2119285905 hasAuthorship W2119285905A5032763504 @default.
• W2119285905 hasAuthorship W2119285905A5054302897 @default.
• W2119285905 hasAuthorship W2119285905A5059429675 @default.
• W2119285905 hasAuthorship W2119285905A5069223833 @default.
• W2119285905 hasAuthorship W2119285905A5069321417 @default.
• W2119285905 hasConcept C118552586 @default.
• W2119285905 hasConcept C126322002 @default.
• W2119285905 hasConcept C139719470 @default.
• W2119285905 hasConcept C142724271 @default.
• W2119285905 hasConcept C15744967 @default.
• W2119285905 hasConcept C162324750 @default.
• W2119285905 hasConcept C197934379 @default.
• W2119285905 hasConcept C203092338 @default.
• W2119285905 hasConcept C204787440 @default.
• W2119285905 hasConcept C27081682 @default.
• W2119285905 hasConcept C2776000289 @default.
• W2119285905 hasConcept C2776412080 @default.
• W2119285905 hasConcept C2776619155 @default.
• W2119285905 hasConcept C2776867660 @default.
• W2119285905 hasConcept C2777198177 @default.
• W2119285905 hasConcept C2779177272 @default.
• W2119285905 hasConcept C2780092697 @default.
• W2119285905 hasConcept C2780199185 @default.
• W2119285905 hasConcept C2781161787 @default.
• W2119285905 hasConcept C3018023364 @default.
• W2119285905 hasConcept C42219234 @default.
• W2119285905 hasConcept C535046627 @default.
• W2119285905 hasConcept C71924100 @default.
• W2119285905 hasConceptScore W2119285905C118552586 @default.
• W2119285905 hasConceptScore W2119285905C126322002 @default.
• W2119285905 hasConceptScore W2119285905C139719470 @default.
• W2119285905 hasConceptScore W2119285905C142724271 @default.
• W2119285905 hasConceptScore W2119285905C15744967 @default.
• W2119285905 hasConceptScore W2119285905C162324750 @default.
• W2119285905 hasConceptScore W2119285905C197934379 @default.
• W2119285905 hasConceptScore W2119285905C203092338 @default.
• W2119285905 hasConceptScore W2119285905C204787440 @default.
• W2119285905 hasConceptScore W2119285905C27081682 @default.
• W2119285905 hasConceptScore W2119285905C2776000289 @default.
• W2119285905 hasConceptScore W2119285905C2776412080 @default.
• W2119285905 hasConceptScore W2119285905C2776619155 @default.
• W2119285905 hasConceptScore W2119285905C2776867660 @default.
• W2119285905 hasConceptScore W2119285905C2777198177 @default.
• W2119285905 hasConceptScore W2119285905C2779177272 @default.
• W2119285905 hasConceptScore W2119285905C2780092697 @default.
• W2119285905 hasConceptScore W2119285905C2780199185 @default.
• W2119285905 hasConceptScore W2119285905C2781161787 @default.
• W2119285905 hasConceptScore W2119285905C3018023364 @default.
• W2119285905 hasConceptScore W2119285905C42219234 @default.
• W2119285905 hasConceptScore W2119285905C535046627 @default.
• W2119285905 hasConceptScore W2119285905C71924100 @default.
• W2119285905 hasLocation W21192859051 @default.
• W2119285905 hasLocation W21192859052 @default.
• W2119285905 hasOpenAccess W2119285905 @default.
• W2119285905 hasPrimaryLocation W21192859051 @default.
• W2119285905 hasRelatedWork W1967365900 @default.
• W2119285905 hasRelatedWork W1980153964 @default.

• next